ORKA · Oruka Therapeutics, Inc. · Stock research

Current Thesis

The setup that was missing in June arrived in July. Oruka spent April through June as a supply story: a $700.4M follow-on priced at $72.50, a 45-day lock-up covering 13,665,080 Fairmount-controlled shares (19.99% of the company) rolling off in mid-June, and a slide from the $91 post-data high into the mid-$50s. On 2026-07-01 Fairmount Healthcare Fund II converted 42,641 Series B preferred into 3,553,410 common and dumped the entire block at $84.43 $300.01M of stock in one print. The tape took it. Shares dipped to $82.22 intraday on 07-03 and then went the other way, closing 2026-07-17 at $92.70, up 11.63% on the session, roughly 5% under the $97.78 fifty-two-week high and +205.8% year-to-date.

That absorption is the leg being bought. A pre-revenue biotech that eats a $300M insider block at the highs and reclaims them inside three weeks is repricing on demand, not on a press release no company announcement explained the 07-17 move. Underneath sits 19.85% short interest, up 32.83% month-over-month, meaning the short base was being added to into an uptrend against a $10.9B M&A comp that printed 2026-06-22. The AbbVie–Apogee deal ($135.11/share for Oruka's Paragon-incubated sister company chasing the same long-acting I&I biologic thesis) reset what this asset class fetches, and Oruka is the most obvious remaining public expression of it. Next company-specific proof is the H2-2026 EVERLAST-A Week 28 and 52-week durability readout, which remains undated the gap between a repriced tape and an unscheduled catalyst is the whole risk.

Bullish and bearish views on Oruka Therapeutics, Inc.

The model's bull view on Oruka Therapeutics, Inc. (ORKA), in brief: Insider block absorbed at the highs (2026-07-01): Fairmount sold 3,553,410 shares at $84.43 for $300.01M. The bear view: Fairmount is not finished. After the 07-01 sale, Fairmount entities still hold 1,131,954 common (Fund II) plus 2,573,308 common (Co-Invest III) plus 94,497 Series B preferred. At the 83.3:1 conversion ratio observed on 07-01, that preferred converts to roughly 7.9M common call… Both cases follow in full.

Bull Case

• Insider block absorbed at the highs (2026-07-01): Fairmount sold 3,553,410 shares at $84.43 for $300.01M. Price closed 2026-07-17 at $92.70, ~10% above the block. The largest identifiable seller printed its exit and the market marked the stock higher.
• Short interest is fuel, not a warning (as of 2026-07-17): 19.85% of float short, up 32.83% in a month, against a stock making 52-week highs. Average daily volume 1.61M shares versus 2.80M traded on 07-17.
• Direct M&A comp at $10.9B (2026-06-22): AbbVie paid $135.11/share for Apogee Therapeutics, its largest deal since Allergan. Both companies were seeded by Paragon Therapeutics and pursue extended-half-life biologics that collapse injection frequency in inflammatory skin disease.
• Best-in-class clinical clearance already banked (2026-04-27): EVERLAST-A Phase 2a of ORKA-001 delivered 63.5% (40/63) PASI 100, 83% PASI 90 and 84% IGA 0/1 at Week 16 PASI 90 above Skyrizi's ~74% benchmark from a molecule with a ~100-day half-life engineered for 6–12-month dosing.
• Delivery partnership de-risks the dosing claim (2026-05-06): global exclusive license to Halozyme's Hypercon technology for ORKA-001 plus one additional target. Halozyme signed only three such deals in early 2026 (Vertex, GSK, Oruka).
• Sell-side raising into strength: BTIG reiterated Buy with a $151 target 2026-07-13; UBS raised to $130 on 07-01, the same day as the Fairmount block; H.C. Wainwright reiterated $120 on 06-23. Consensus average $134.30 across 11 analysts, range $85–$160.
• Funded past the binaries: ~$1.1B cash after the 9,660,000-share offering at $72.50, current ratio 23.76. Operations are covered through the 2027 EVERLAST-B and ORKA-002 readouts, so the standard clinical-biotech dilution reflex is off the table near term.
• M&A structure widened just before the comp (2026-05-29): the Paragon amendment extended the ORKA-001 license to all indications including IBD and added change-of-control language that accelerates timelines.

Bear Case

• Fairmount is not finished. After the 07-01 sale, Fairmount entities still hold 1,131,954 common (Fund II) plus 2,573,308 common (Co-Invest III) plus 94,497 Series B preferred. At the 83.3:1 conversion ratio observed on 07-01, that preferred converts to roughly 7.9M common call it ~11.6M shares, near $1.1B at current price, held by a seller that has demonstrated exactly what it does when it can.
• The next catalyst has no date. H2-2026 is the guidance for EVERLAST-A Week 28 and the 52-week durability subset. A stock at 95% of its 52-week high with an unscheduled next event is carrying full catalyst premium with no clock running.
• Real binaries are 2027, not this year: EVERLAST-B Phase 2b (PASI 100 at Week 16) and ORKA-002 Phase 2. Everything before then is intermediate data on a cohort of 63 patients.
• $5.59B market cap on zero revenue. Price-to-book 9.57, expected EPS ($2.49). The valuation is a discounted probability of a 2027 outcome and a takeout bid that no one has made.
• The M&A leg is inference. AbbVie bought Apogee; nobody has bid for Oruka. Sympathy-comp premium decays if a quarter passes with no strategic interest and no data.
• Single-asset concentration. ORKA-002 is Phase 1 (75–80-day half-life disclosed 2026-01-12). A safety signal or durability disappointment in ORKA-001 takes most of the equity value with it.
• Insider selling with no offset: ~$12M of insider sales over the trailing three months and no open-market insider buying to corroborate the tape.

Setup & Price Structure

Fifty-day range $55.01–$95.17 against a 52-week range of $12.84–$97.78 the stock has traded a 73% band in ten weeks. The June low in the $55–$64 zone is the base that formed while the lock-up expiry and offering supply cleared. The relevant shelf now is $82–$84: the 07-03 low of $82.22 and the $84.43 Fairmount block price mark where a $300M supply event was digested. Holding above that zone is what makes the 07-17 breakout a real one.

The upside reference is $97.78. A daily close through it puts the stock in unbroken price discovery with 19.85% of the float short and no overhead supply from any prior holder except Fairmount's remaining stake. Beneath the shelf, the next structural level is $72.50 the May follow-on price, where the marginal institutional buyer of the last raise sits at breakeven.

On the beginner-trap matrix: this is extended, not blown off. Up 205.8% YTD and 5% from the high qualifies as stretched, and a fresh entry here is buying strength by definition. It is not peak-retail the 07-17 move came on 1.7x average volume with no press release and no visible retail catalyst, which reads institutional. No earnings inside three trading days. What it is not is a name to size into on weakness: below the $82 shelf the supply thesis is back and there is nothing to add to.

Character: Binary Catalyst. The equity is a probability-weighted claim on ORKA-001 data plus takeout optionality, and it will move in gaps, not glides.

Catalyst Calendar (next 30 days)

• ~2026-08-11 (est., range 2026-08-10 to 2026-08-17) Q2 2026 results. Not officially scheduled; verify on IR before any entry inside three trading days. H.C. Wainwright models ($0.56) EPS versus the Q1 print of ($0.48) vs ($0.53) consensus on 2026-05-13. For a pre-revenue name the print matters only for cash burn and any timing language on the H2 readout.
• Rolling, through 2026-08-18 Form 4 / 13D-A filings from Fairmount entities. The 07-01 conversion-and-sale pattern is repeatable against 94,497 remaining Series B preferred. EDGAR is the leading indicator here, and each filing is a same-day supply event.
• Undated, H2 2026 EVERLAST-A Week 28 efficacy across all patients plus 52-week follow-up on a subset. Company has not narrowed the window. Any 8-K pre-announcing a data date is itself a tradeable event.
• No PDUFA, no advisory committee, no regulatory decision in the window. Nothing forces a repricing before the Q2 print.

What Would Change Our Mind

• A daily close below $82 breaks the July absorption shelf and reclassifies the 07-01 Fairmount block as distribution that the market briefly papered over. The move from $82 to $92.70 was the entire bull argument for the current leg.
• A weekly close below $72.50 the May follow-on price puts every buyer from the raise underwater and re-opens the supply narrative that dominated May and June.
• A new Fairmount Form 4 showing conversion and sale that the tape does not absorb meaning a block prints and price fails to reclaim the block price within roughly two weeks, the opposite of what happened in July.
• Guidance slipping the EVERLAST-A Week 28 / 52-week readout from H2 2026 into 2027 on the Q2 call. That removes the only near-dated company-specific event and leaves a $5.59B valuation with nothing to trade against until the 2027 binaries.
• A durability miss when the data lands: Week 28 PASI 100 materially below the 63.5% Week 16 figure would undercut the once-or-twice-yearly dosing claim that separates this asset from Skyrizi and bimekizumab, and it would take the takeout comp with it.
• AbbVie or a peer acquiring a different long-acting I&I asset the comp premium is scarcity-based, and a second buyer choosing someone else prices Oruka as a standalone development story.
• Confirmation, not invalidation: a daily close above $97.78 on above-average volume with short interest still near 20% would argue the squeeze leg has started and the correct read shifts to riding it rather than waiting for data.

Correlation Notes

• Immunology M&A complex: trades against APGE (until the AbbVie close), and the broader long-acting biologics group. The 2026-06-22 AbbVie print moved this cohort together; ORKA jumped 18% on the day on someone else's news, which is the definition of comp-driven correlation. Expect it to re-rate on peer deal headlines with no ORKA input.
• Paragon Therapeutics lineage is the tightest linkage anything that validates or damages the incubator's platform economics reads directly through to Oruka.
• Established IL-23/IL-17 incumbents (AbbVie's Skyrizi, UCB's bimekizumab, J&J's Tremfya) are the inverse read: label expansions or dosing-interval improvements from the incumbents compress the differentiation Oruka is priced for.
• XBI beta is high but not the driver. With 19.85% short interest and a 73% ten-week range, idiosyncratic flow dominates the biotech index correlation on any given day. A broad risk-off tape hurts, but the stock has been making its own weather since April.
• Halozyme (HALO) carries a small reflexive linkage through the Hypercon license, though the read-through runs Oruka-to-Halozyme rather than the reverse.
• Data-quality note: several retail data aggregators currently mis-describe Oruka as an oncology company with a lead candidate "ONCT-01," an artifact of the shell entity (CIK 907654, formerly ARCA biopharma) the company merged into. Screens built on those feeds will misclassify the name into the wrong peer set.